A 53-year-old Texas rancher developed a blistering skin rash that was sensitive to exposure to sunlight. He was referred to hematology with a presumptive diagnosis of porphyria. His peripheral blood counts were within normal limits, and a bone marrow examination revealed erythroid dyspoiesis and ringed sideroblasts. Serum, plasma, and erythrocyte protoporphyrin levels were elevated, the findings of which are consistent with a diagnosis of erythropoietic protoporphyria. This paper discusses the diagnosis and etiology of the porphyrias.
Because of the clinical suspicion and the pathologic fi ndings of erythroid dyspoiesis and ring sideroblasts, a peripheral blood sample was sent for testing of protoporphyrin levels. Th e total plasma porphyrins were 46.9 μg/dL (reference range, <1.0), total serum porphyrins were 784 nmol/L (reference range, 0-15), erythrocyte protoporphyrins were 300 umol/mol heme (reference range, <70), and the fractionation of plasma porphyrins (emission spectrum) was at a wave length suggestive of erythropoietic protoporphyria (EPP). With the positive results, he was considered to have EPP secondary to a myelodysplastic syndrome, refractory anemia with ring sideroblasts.
Th e patient's peripheral blood was sent for sequencing of his ferrochelatase gene, which showed a c.913G>T change in exon 9 which altered the canonical splice site and was therefore predicted to be deleterious. His skin disease has been well controlled with Lumitene, a high-dose beta-carotene supplement, and sun avoidance. Th e patient has been monitored with complete blood counts synthesis stalls at the last step when ferrochelatase has insuffi cient iron to add to the accumulating protoporphyrins ( 2 ) . The protoporphyrins deposit in the liver, erythrocytes, and plasma and are highly toxic. Th e mechanism of the direct toxicity is poorly understood; however, the photodynamic reactions are. Th e molecule is hydrophobic, favoring lipid bilayers, like cell membranes. In the superfi cial vasculature of the skin, protoporphyrins in erythrocytes and plasma are exposed to light. Absorbing light at 320 to 595 nm, protoporphyrin is excited to a triplet state. Th e energy transfer is propagated to oxygen, resulting in reactive oxygen species. Th e pathogenic consequence is oxidative damage of proteins, lipids, and nucleic acids. Among its eff ects, this phenomenon can activate complement and degranulate mast cells. Th e histopathologic fi ndings are consistent with the cycle of damage and repair. Th e blood vessels of the basal lamina thicken with perivascular hyaline material and proliferate for the sake of perfusion ( 2 ) .
Th e liver is tasked with the excretion of the excess protoporphyrins. If its capacity is overwhelmed, the protoporphyrins are deposited in hepatocytes. Birefringent crystals, characterized by Maltese cross shapes, are visible within the deposits. Th e liver reacts as it would to any chronic insult with regeneration and fi brosis potentially leading to cirrhosis ( 2 ) . Th e conventional histologic bone marrow pathology is not as striking. Increased ring sideroblasts by light microscopy have been described, but in a greater number of cases there is ultrastructural evidence of iron deposition in the mitochondria of erythroblasts ( 4 ). In acquired forms of the disease, the apparent histopathology will be that of the underlying myelodysplastic or myeloproliferative disease. A microcytic anemia may be seen in the inherited X-linked dominant EPP with decreases in iron stores and hemoglobin ( 5 ) .
Th e laboratory investigation of EPP requires fi nding elevated protoporphyrins in erythrocytes, plasma, and feces, as in this case. Protoporphyrins are not excreted in urine. Protoporphyrins are exquisitely light sensitive. Since plasma concentrations fall rapidly upon exposure to light, measurement of erythrocyte protoporphyrin is usually preferred ( 6 ) . and metabolic profi les every 2 to 3 months since diagnosis and has required no other treatment. His liver enzymes have been normal except for bilirubin, which has mildly risen to 2.2 mg/dL. A bone marrow transplant is planned.
DISCUSSION
Th e porphyrias are a collection of diseases caused by inborn and acquired errors of heme synthesis. Heme is necessary for several types of hemoproteins, including liver and respiratory cytochromes, but hemoglobin synthesis for red blood cells accounts for the vast majority of heme synthesis in humans. Th e synthesis of the heme molecule, a heterocyclic organic ring surrounding an iron ion, is catalyzed in eight steps from succinyl coenzyme A and glycine ( Figure 2 ). Th ese eight enzymes are encoded on nine diff erent genes, each with described mutations. Two genes encode isoenzymes that catalyze the fi rst step in the pathway; one is erythroid specifi c, aminolevulinic acid synthase 2 (ALAS2). A loss of function mutation at any step marks a stop in the synthetic pathway and an accumulation of precursor molecules. Th ese precursors have no physiologic function, are not normally detected at signifi cant levels, and are toxic to varying degrees. Tight regulatory control is necessary and is cell type specifi c. In erythroid precursors, iron availability is required for the translation of the ALAS2 mRNA. Th e eighth step is also iron dependent, as ferrochelatase must add an iron ion to each protoporphyrin. In the liver, heme itself represses the translation of the fi rst and rate-limiting enzyme, ALAS1 ( 1 ).
Except in rare cases, EPP is an inherited form of ferrochelatase defi ciency or malfunction or an erythroid-specifi c ALAS2 enzyme gain of function mutation ( Figure 2 ) . Th e genetics of these diseases are complex, with forms with low penetrance and late onset. Acquired forms of EPP are caused by somatic mutations of the ferrochelatase gene often associated with the genetic instability of an underlying myelodysplastic or myeloproliferative disorder ( 2 ) . Th e immediate pathology of EPP is the accumulation of protoporphyrin, the last substrate in the synthesis of heme. Loss of function mutation in the enzyme ferrochelatase, found on chromosome 18, is usually the culprit ( 3 ). Rarely, a gain of function mutation of the erythroidspecifi c enzyme ALAS2, found on the X chromosome, increases the turnover of the pathway ( 1 ) . As the mutant ALAS2 continues to drive the biosynthesis without regard to the availability of iron, the 
